You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,688,760

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,688,760

Title:	Polypeptides having bone resorption inhibitory activity comprising PTHrP-derived sequences
Abstract:	Polypeptides comprising an N-terminal amino acid sequence corresponding to amino acids 107-111 of parathyroid hormone related protein (PTHrP) having bone resorption inhibitory activity are provided. The polypeptides are provided in pharmaceutical compositions for the treatment of diseases and disorders where inhibition of bone resorption is indicated.
Inventor(s):	Kemp; Bruce E. (Kew, AU), Nicholson; Geoffrey C. (Geelong, AU), Martin; Thomas J. (Kew, AU), Fenton; Anna J. (Geelong, AU), Hammonds; R. Glenn (Berkeley, CA)
Assignee:	Genentech, Inc. (San Francisco, CA) The University of Melbourne (Victoria, AU)
Application Number:	08/064,111
Patent Claims:	1. A polypeptide having bone resorption inhibitory activity, said polypeptide having an amino acid sequence: wherein: Xaa.sub.1 is an amino acid selected from the group consisting of Thr, Ala, Cys, Pro, D-Trp and n-methylalanine; Xaa.sub.2 is an amino acid selected from the group consisting of Arg, Lys, His, and D-Ala; Xaa.sub.3 is an amino acid selected from the group consisting of Ser, Ala, Cys, and D-Ser; Xaa.sub.4 is an amino acid selected from the group consisting of Ala, n-methylalanine, (3-(2-napthyl)-alanine), and D-Arg; Xaa.sub.5 is an amino acid selected from the group consisting of Tyr, Trp, D-Thr, .alpha.-phenylglycine, and .alpha.-napthylalanine; Z is present or absent, and when present consists of an amino acid sequence beginning at PTHrP amino acid residue 112 as shown in FIG. 1 (SEQ ID NO:1) and ending at any PTHrP amino acid from 112 to 173 as shown in FIG. 1 (SEQ ID NO:1); or wherein Xaa.sub.1 -Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Xaa.sub.5 -Z is the sequence RTRSAW (SEQ ID NO:4) or TRCAWPGTC (SEQ ID NO:15), and where "D" refers to the D-amino acid isomer; excluding PTHrP(107-138) and PTHrP(107-141). 2. The polypeptide according to claim 1 wherein the amino acid sequence Xaa.sub.1 -Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Xaa.sub.5 consists of amino acids 107-111 of the parathyroid hormone related protein (PTHrP) shown in FIG. 1 (SEQ ID NO:1). 3. The polypeptide according to claim 2, wherein the polypeptide is a fragment of the PTHrP shown in FIG. 1 (SEQ ID NO:1), wherein the fragment is selected from the group consisting of: PTHrP (107-111) PTHrP (107-112) PTHrP (107-113) PTHrP (107-114) PTHrP (107-115) PTHrP (107-116) PTHrP (107-117) PTHrP (107-118) PTHrP (107-119) PTHrP (107-120) PTHrP (107-121) PTHrP (107-122) PTHrP (107-123) PTHrP (107-124) PTHrP (107-125) PTHrP (107-126) PTHrP (107-127) PTHrP (107-128) PTHrP (107-129) PTHrP (107-130) PTHrP (107-131) PTHrP (107-132) PTHrP (107-133) PTHrP (107-134) PTHrP (107-135) PTHrP (107-136) PTHrP (107-137) PTHrP (107-139) PTHrP (107-140) PTHrP (107-142) PTHrP (107-143) PTHrP (107-144) PTHrP (107-145) PTHrP (107-146) PTHrP (107-147) PTHrP (107-148) PTHrP (107-149) PTHrP (107-150) PTHrP (107-151) PTHrP (107-152) PTHrP (107-153) PTHrP (107-154) PTHrP (107-155) PTHrP (107-156) PTHrP (107-157) PTHrP (107-158) PTHrP (107-159) PTHrP (107-160) PTHrP (107-161) PTHrP (107-162) PTHrP (107-163) PTHrP (107-164) PTHrP (107-165) PTHrP (107-166) PTHrP (107-167) PTHrP (107-168) PTHrP (107-169) PTHrP (107-170) PTHrP (107-171) PTHrP (107-172) and; PTHrP (107-173). 4. The polypeptide according to claim 2 or 3 wherein the amino terminus of amino acid 107 of PTHrP is protected with a hydrolyzable protecting group. 5. The polypeptide according to claim 1 wherein the amino acid residue Xaa.sub.1 is protected with a hydrolyzable protecting group. 6. The polypeptide according to claim 1 selected from the group consisting of: T R S A W (SEQ ID NO:3) A R S A W (SEQ ID NO:8) meA R S A W (SEQ ID NO:19) R T R S A W (SEQ ID NO:4) T R S A Y (SEQ ID NO:13) T R A A W (SEQ ID NO:10) A R A A W (SEQ ID NO:11) .sub.D W.sub.D A.sub.D S.sub.D R.sub.D T T R C A W P G T C (SEQ ID NO:15) P R S A W (SEQ ID NO:7) T K S A W (SEQ ID NO:9) T R S meA W (SEQ ID NO:12) T R S A .phi.G (SEQ ID NO:14) T H S A W (SEQ ID NO:16) and T R S A npA, (SEQ ID NO:20) where "D" refers to the D-amino acid isomer; .phi.G is .alpha.-phenylglycine; meA is n-methylalanine; npA is 3(2-napthyl)alanine. 7. A composition which comprises the polypeptide according to claim 1 in association with one or more pharmaceutically acceptable carriers or excipients. 8. A method for the inhibition of bone resorption in a subject, which method comprises administering a bone resorption inhibitory amount of the polypeptide as claimed in claim 1, optionally in association with at least one pharmaceutically acceptable carrier or excipient. 9. The method according to claim 8 wherein said polypeptide is a fragment of the PTHrP shown in FIG. 1 (SEQ ID NO:1), wherein the fragment is selected from the group consisting of: PTHrP (107-111) PTHrP (107-112) PTHrP (107-113) PTHrP (107-114) PTHrP (107-115) PTHrP (107-116) PTHrP (107-117) PTHrP (107-118) PTHrP (107-119) PTHrP (107-120) PTHrP (107-121) PTHrP (107-122) PTHrP (107-123) PTHrP (107-124) PTHrP (107-125) PTHrP (107-126) PTHrP (107-127) PTHrP (107-128) PTHrP (107-129) PTHrP (107-130) PTHrP (107-131) PTHrP (107-132) PTHrP (107-133) PTHrP (107-134) PTHrP (107-135) PTHrP (107-136) PTHrP (107-137) PTHrP (107-139) PTHrP (107-140) PTHrP (107-142) PTHrP (107-143) PTHrP (107-144) PTHrP (107-145) PTHrP (107-146) PTHrP (107-147) PTHrP (107-148) PTHrP (107-149) PTHrP (107-150) PTHrP (107-151) PTHrP (107-152) PTHrP (107-153) PTHrP (107-154) PTHrP (107-155) PTHrP (107-156) PTHrP (107-157) PTHrP (107-158) PTHrP (107-159) PTHrP (107-160) PTHrP (107-161) PTHrP (107-162) PTHrP (107-163) PTHrP (107-164) PTHrP (107-165) PTHrP (107-166) PTHrP (107-167) PTHrP (107-168) PTHrP (107-169) PTHrP (107-170) PTHrP (107-171) PTHrP (107-172) and; PTHrP (107-173). 10. The method according to claim 8 wherein the amino acid sequence Xaa.sub.1 -Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Xaa.sub.5 consists of amino acids 107-111 of the parathyroid hormone related protein (PTHrP) shown in FIG. 1 (SEQ ID NO:1). 11. The method according to claim 8 wherein said polypeptide is selected from the group consisting of: T R S A W (SEQ ID NO:3) A R S A W (SEQ ID NO:8) meA R S A W (SEQ ID NO:19) R T R S A W (SEQ ID NO:4) T R S A Y (SEQ ID NO:13) T R A A W (SEQ ID NO:10) A R A A W L (SEQ ID NO:11) .sub.D W.sub.D A.sub.D S.sub.D R.sub.D T T R C A W P G T C (SEQ ID NO:15) P R S A W (SEQ ID NO:7) T K S A W (SEQ ID NO:9) T R S meA W (SEQ ID NO:12) T R S A .phi.G (SEQ ID NO:14) T H S A W (SEQ ID NO:16) and T R S A npA, (SEQ ID NO:20) where "D" refers to the D-amino acid isomer; .phi.G is .alpha.-phenylglycine; meA is n-methylalanine; npA is 3(2-napthyl)alanine. 12. A method according to claim 8 which is a method for the amelioration of bone resorption associated with zero gravity. 13. The method according to any of claims 9-11 wherein the amino terminal amino acid is protected with a hydrolyzable protecting group. 14. A method for the treatment of diseases characterized by excess bone resorption which method comprises administering to a subject in need of such treatment a bone resorption inhibitory amount of the polypeptide according to claim 1, optionally in association with a pharmaceutically acceptable carrier or excipient. 15. The method according to claim 14 wherein said polypeptide is a fragment of the PTHrP shown in FIG. 1 (SEQ ID NO:1), wherein the fragment is selected from the group consisting of: PTHrP (107-111) PTHrP (107-112) PTHrP (107-113) PTHrP (107-114) PTHrP (107-115) PTHrP (107-116) PTHrP (107-117) PTHrP (107-118) PTHrP (107-119) PTHrP (107-120) PTHrP (107-121) PTHrP (107-122) PTHrP (107-123) PTHrP (107-124) PTHrP (107-125) PTHrP (107-126) PTHrP (107-127) PTHrP (107-128) PTHrP (107-129) PTHrP (107-130) PTHrP (107-131) PTHrP (107-132) PTHrP (107-133) PTHrP (107-134) PTHrP (107-135) PTHrP (107-136) PTHrP (107-137) PTHrP (107-139) PTHrP (107-140) PTHrP (107-142) PTHrP (107-143) PTHrP (107-144) PTHrP (107-145) PTHrP (107-146) PTHrP (107-147) PTHrP (107-148) PTHrP (107-149) PTHrP (107-150) PTHrP (107-151) PTHrP (107-152) PTHrP (107-153) PTHrP (107-154) PTHrP (107-155) PTHrP (107-156) PTHrP (107-157) PTHrP (107-158) PTHrP (107-159) PTHrP (107-160) PTHrP (107-161) PTHrP (107-162) PTHrP (107-163) PTHrP (107-164) PTHrP (107-165) PTHrP (107-166) PTHrP (107-167) PTHrP (107-168) PTHrP (107-169) PTHrP (107-170) PTHrP (107-171) PTHrP (107-172) and; PTHrP (107-173). 16. The method according to claim 14 wherein the amino acid sequence Xaa.sub.1 -Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Xaa.sub.5 consists of amino acids 107-111 of the parathyroid hormone related protein (PTHrP) shown in FIG. 1 (SEQ ID NO:1). 17. A method according to claim 14 wherein said polypeptide is selected from the group consisting of: T R S A W (SEQ ID NO:3) A R S A W (SEQ ID NO:8) meA R S A W (SEQ ID NO:19) R T R S A W (SEQ ID NO:4) T R S A Y (SEQ ID NO:13) T R A A W (SEQ ID NO:10) A R A A W (SEQ ID NO:11) .sub.D W.sub.D A.sub.D S.sub.D R.sub.D T T R C A W P G T C (SEQ ID NO:15) P R S A W (SEQ ID NO:7) T K S A W (SEQ ID NO:9) T R S meA W (SEQ ID NO:12) T R S A .phi.G (SEQ ID NO:14) T H S A W (SEQ ID NO:16) and T R S A npA, (SEQ ID NO:20) where "D" refers to the D-amino acid isomer; .phi.G is .alpha.-phenylglycine; meA is n-methylalanine; npA is 3(2-napthyl)alanine. 18. A method according to claim 14 wherein said diseases are selected from the group consisting of osteoporosis, Paget's disease of bone, humoral hypercalcemia of malignancy and metastic bone diseases. 19. The method according to any of claims 15-17 wherein the amino terminal amino acid is protected with a hydrolyzable protecting group.

Details for Patent 5,688,760

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2014-11-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.